<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="1" ids="24261">Glucocorticoid</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is exploited for the treatment of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Innate and acquired resistance limits treatment efficacy; however, resistance mechanisms are not well understood </plain></SENT>
<SENT sid="2" pm="."><plain>Previously, using WEHI7.2 murine thymic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells, we found that increasing the resistance to <z:chebi fb="17" ids="16240">hydrogen peroxide</z:chebi> (<z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi>) by catalase transfection or selection for <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> resistance caused <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> resistance </plain></SENT>
<SENT sid="3" pm="."><plain>This suggests the possibility that increasing <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> sensitivity could sensitize the cells to <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In other cell types, increasing <z:chebi fb="70" ids="18291,35154">manganese</z:chebi> <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (MnSOD) can increase intracellular <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The current study showed that increased expression of MnSOD sensitized WEHI7.2 cells to <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment of WEHI7.2 cells with the catalytic <z:chebi fb="11" ids="22586">antioxidant</z:chebi> Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)<z:chebi fb="2" ids="8337">porphyrin</z:chebi> (MnTE-2-PyP(5+)), a manganoporphyrin, mimicked the effects of increased MnSOD expression </plain></SENT>
<SENT sid="7" pm="."><plain>MnTE-2-PyP(5+) also sensitized WEHI7.2 cells to <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and inhibited cell growth; it had no effect on the WEHI7.2 cell response to <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> or <z:chebi fb="0" ids="28445">vincristine</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>In primary follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells, MnTE-2-PyP(5+) increased cell <z:hpo ids='HP_0011420'>death</z:hpo> due to <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment of H9c2 cardiomyocytes with MnTE-2-PyP(5+) inhibited <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> cytotoxicity </plain></SENT>
<SENT sid="10" pm="."><plain>The profile of MnTE-2-PyP(5+) effects suggests MnTE-2-PyP(5+) has potential for use in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> that are treated with <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> </plain></SENT>
</text></document>